The effect of cimepilimab in the treatment of non-small cell lung cancer

Cemiplimab (Cemiplimab): It is an immune checkpoint inhibitor. As an inhibitor of programmed cell death protein 1 (PD-1), it enhances the body's immune response to tumor cells by lifting the suppression of the immune system. Since cimepilimab was approved for the treatment of non-small cell lung cancer (NSCLC), it has demonstrated significant efficacy in the treatment of this disease, especially in patients with advanced or metastatic lung cancer for whom conventional treatments have limited efficacy.

Non-small cell lung cancer is the most common type of lung cancer, and its prognosis is usually poor, especially for those patients who are in an advanced or metastatic state at the time of diagnosis, and traditional chemotherapy and radiotherapy may not be able to effectively control the disease. In this case, immunotherapy has become a new hope for the treatment of non-small cell lung cancer. Cimepilimab restores the killing function of the immune system by inhibiting PD-1, allowing the body to effectively recognize and attack tumor cells. This type of immunotherapy is particularly useful for patients who have developed resistance to or cannot tolerate traditional chemotherapy.

In addition, when treating lung cancer, cimepilimab is often used in combination with other treatments, such as chemotherapy drugs, to enhance the therapeutic effect. Compared with traditional treatment methods, cimepilimab provides a new treatment approach that can delay disease progression and improve patients' quality of life, especially when the disease is difficult to control through surgery or radiotherapy.

Although side effects may have some impact on patients, most immune-related side effects are reversible. During treatment, doctors often make adjustments based on the severity of side effects, including discontinuing the drug or using immunosuppressive drugs to relieve symptoms. Regular monitoring of patients' blood indicators, liver and kidney function, and immune system status is the key to ensuring safe medication use.

Reference materials:https://www.libtayohcp.com/